Dietary Nondigestible Polysaccharides Ameliorate Colitis by Improving Gut Microbiota and CD4+ Differentiation, as Well as Facilitating M2 Macrophage Polarization

Authors:

Abstract
Background: The aim of this study was to investigate the therapeutic mechanism of a specific multifiber mix diet (MF) designed to match the fiber content of a healthy diet in interleukin‐10 knockout (IL‐10−/−) mice with spontaneous chronic colitis displaying similar characteristics to those of human Crohn's disease (CD).Methods: Sixteen‐week‐old IL‐10−/− mice were used for the experiments with MF diet for 4 weeks. Severity of colitis, the composition of the fecal microbiota, expression of Th1/Th17 cells, myeloperoxidase (MPO) concentrations, and inflammatory cytokines and chemokines (tumor necrosis factor‐α [TNF‐α], IL‐6, macrophage inflammatory protein [MIP]‐2, monocyte chemoattractant protein‐1 [MCP‐1], and MIP‐1α), as well as arginase 1 (Arg1) and signal transducers and activators of transcription 6 (STAT6) proteins, were measured at the end of the experiment. In addition, the corresponding metabolites (short‐chain fatty acids) of MF on CD4+CD25+Foxp3+ regulatory T cells (Tregs) were also detected in vivo and in vitro.Results: MF treatment significantly ameliorated colitis associated with decreased lamina propria frequency of Th1/Th17 cells, MPO concentrations, and inflammatory cytokines and chemokines (TNF‐α, IL‐6, MIP‐2, MCP‐1, and MIP‐1α). An increase in gut microbial diversity was observed after MF treatment compared with IL‐10−/− mice, including a significant increase in bacteria belonging to the Firmicutes phylum and a significant decrease in bacteria belonging to the Proteobacteria phylum. Moreover, MF treatment increased the differentiation of CD4+CD25+Foxp3+ Tregs mainly by microbial metabolites butyrate. In addition, Arg1 and STAT6 proteins were also significantly increased after MF treatment.Conclusions: These results shed light on the contribution of MF treatment to the CD mouse model and suggest that MF has potential as a therapeutic strategy for enhancing efficacy in inducing remission in patients with active CD.
Funding Information
  • National Natural Science Foundation of China (81600434)
  • China Postdoctoral Science Foundation (2018M630581)
  • Natural Science Foundation of Jiangsu Province (BK 20160572, BK 20170358)

This publication has 42 references indexed in Scilit: